Clinical trial
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Renal Function
NCT02441829 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Renal Function
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2015
- Completion date
- December 31, 2015
- Enrollment
- 55 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.